About Moshe Rogosnitzky
Real-world Drug Repurposing
Real-world drug repurposing – the immediate “off-label” prescribing of drugs to address urgent clinical needs – is a widely overlooked opportunity, which I am determined to address, so that access to repurposed drugs becomes mainstream. I am one of numerous expert physicians, scientists, government agency officials, and nonprofit leaders around the world who believe that solutions to chronic and life-endangering medical problems lie in the rediscovery and repurposing of widely used, low-cost, and clinically proven safe medicines. Real-world drug repurposing is the only sustainable option to prevent and treat current and future health crises such as the COVID-19 epidemic.
Optimal real-world drug repurposing requires treatment possibilities with a solid track record of safety, affordability, and access.
Fortunately, many thousands of such drugs are already available, however, there is no central repository of off-label drug repurposing information that enables immediate intervention in times of public and personal health crises. My work is focused on changing this and ensuring that life-saving information is freely accessible to all, in real-time.
Research Scientist
As a research scientist, I have had the honor of working on highly rewarding collaborations with researchers at leading academic institutions including:
- Johns Hopkins University (Baltimore, Maryland)
- Hershey Medical Center, Penn State University (Hershey, Pennsylvania)
- University Hospital of Lille (Lille, France)
- Hadassah University Hospital (Jerusalem, Israel)
- St. George’s University Hospital (London, U.K.)
- University of Southern California (San Diego, California)
- University of Toronto (Toronto, Ontario)
- Baylor College of Medicine (Houston, Texas)
- Ariel University (Ariel, Israel)
- All India Institute of Medical Science (Delhi, India)
- Postgraduate Institute of Medical Education & Research (Chandigarh, India)
Medical Innovator
An innovator in drug repurposing, I am a named inventor on numerous patents in many therapeutic fields including:
- SARS
- Prostate cancer
- Crohn’s disease
- Dry eye disease
- Pterygium
- Pinguecula
- Viral conjunctivitis
- Insomnia
- Viral infections
- Hemostasis
- Androgenic alopecia
- Erectile dysfunction
- Pain disorders
- Medical-information systems.
Consulting & Public Speaking
I have had the honor of collaborating with, consulting with and speaking as a guest at conferences organized by a number of organizations, including:
- Many Personalized Oncology Expert Panels regarding multiple cancer types (including pancreatic, lung, esophageal, metastatic melanoma, glioblastoma, and sarcoma).
- Pharmaceutical conferences in North America and Asia, as well as guest lecturing for the Israeli Government Ministry of Health
- As the Founder and Director of multiple drug repurposing start-ups, I have presented my unique approach to drug repurposing to audiences at Massachusetts Institute of Technology (MIT) in Cambridge, and Charite Health Innovation Summit in Berlin.
Philanthropist & Teacher
- Since 1999, I have led the preparation of personalized treatment plans for cancer patients that have focused on real-world drug repurposing interfaced with cutting-edge diagnostics to achieve high-impact treatment strategies.
- I believe that patients should have the knowledge to make informed decisions about their health. I oversee the synthesis of published medical research into comprehensive, consumer-friendly summaries through my work as Co-Founder and Research Director of the non-profit MedInsight Research Institute.
- At MedInsight, I also created LDNscience.org – the largest physician and patient public information site for Low Dose Naltrexone (LDN) – a treatment that I helped take from obscurity to wide-spread use by more than 500,000 patients worldwide, in more than 60 diseases.
Moshe Rogosnitzky at Work

Charité Entrepreneur Summit, Berlin
Moshe Rogosnitzky as member of Drug Repurposing Panel at Charité Berlin Institute for Health Summit 2019 with Joann Halpern, Director of Hasso-Plattner-Institute, New York; Nektarios Oraiopoulos of Cambridge Judge Business School; Armin Schneider of Molecular Health in Heidelberg; and Andrew Whittaker of Astrazeneca Pharmaceuticals, UK.
Video

Presentation

Talk

Interview
With Josh Reinstein of Israel Now News November 2020.